Hyphens Pharma International Limited has earnings of $2.2 million for 2QFY20, up 32% y-o-y, on the back of a 4.1% y-o-y growth in revenue to $30.2 million.
The company’s main business lines all enjoyed higher turnover, with growth especially strong from its proprietary brands of products.
“Despite the good result achieved in 1H2020, we are cognisant of the very challenging and unpredictable business environment due to COVID-19,” said Lim See Wah, executive chairman and CEO.
“Thus, we will remain diligent and agile as we navigate our path forward,” he added.
While the company is seeing mixed performance across its various distribution channels: retail’s growing but there’s a slowdown from the medical channels.
“The recovery of market demand in the regions had been inconsistent and unpredictable, and any further lockdown measures implemented will have a negative impact on the Group’s business.”
